默沙东2024年业绩新鲜出炉:制药板块实现营收574亿美元,同比增长7%。其核心产品K药依旧强势,实现营收295亿美元,同比增长18%。然而,默沙东的困境已现。K药成为众矢之的,被MNC和国内Biotech头对头围猎。而其核心专利将于2028年到期,届时将陷入大量生物类似药的围攻。另外一款重磅药物HPV九价疫苗Gardasil 9已先于K药进入失速状态。2024年销售额86亿美元,同比下降3%。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.